Thursday, April 18, 2013/Oraya Therapeutics’ INTREPID Study Published in Ophthalmology, the official Journal of the American Academy of Opthalmolgy
NEWARK, CA (Apr 18, 2013) — Oraya Therapeutics, Inc. today announced that results of its INTREPID study evaluating the safety and efficacy of Oraya Therapy™ Stereotactic Radiotherapy for the treatment of Wet Age-Related Macular Degeneration (AMD) have now been published, on-line in the leading peer-reviewed journal Ophthalmology. The study met primary endpoints, showing that a single dose of Oraya Therapy significantly reduces the need for anit-VEGF injections for patients with Wet AMD, with a favorable safety profile one year after administration.
Thursday, April 4, 2013/New Therapy for Wet AMD Introduced in Switzerland by Oraya® Therapeutics and EyeRAD
NEWARK, CA and BASEL, SWITZERLAND (Apr 4, 2013) — Oraya Therapeutics, Inc. and EyeRAD announced today that agreements have been reached to establish the Vista Klinik in Basel as one of the world’s first centers to offer the Oraya Therapy™ for the treatment of wet age-related macular degeneration (AMD), the leading cause of blindness in people over 65 in the Western world.
Wednesday, February 27, 2013/Oraya Therapy™ Continues to Show Efficacy for Wet Age-Related Macular Degeneration
NEWARK, CA. (FEB. 27, 2013) – Oraya Therapeutics, Inc. today announced that one of the patients who successfully was treated for wet age-related macular degeneration (AMD) with Oraya Therapy™ during the INTREPID clinical trial has released data showing he has experienced significant, sustained vision improvement more than two years after treatment in his right eye, without any subsequent anti-vascular endothelial growth factor (anti-VEGF) injections or other treatment.
>> Download Document
Tuesday, December 11, 2012/New Therapy for Wet AMD Launched by Oraya Therapeutics and Optegra Eye Hospital Group
NEWARK, CA and LONDON, UK. (December 11, 2012) — Oraya Therapeutics, Inc. announced today that an agreement has been reached with UK specialist eye hospital group Optegra, to establish Optegra as the world’s first clinical centers to offer Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet Age-related Macular Degeneration (AMD).
Thursday, November 22, 2012/Trial Data Show Oraya Therapy Significantly Reduces Anti-VEGF Injections For Wet AMD
Oraya Therapeutics, Inc. today announces exciting late breaking results from a further analysis of the INTREPID trial using Oraya’s IRay® Radiotherapy System for wet AMD. The initial results were first presented during the 12th EURETINA Congress in Milan, Italy in September.
Thursday, September 20, 2012/Oraya Therapeutics Successful INTREPID Study Outcomes Presented at EURETINA 2012 Congress
Oraya Therapeutics, Inc. today announced that results of the INTREPID trial of radiation therapy for wet AMD were first presented during the 12th EURETINA Congress in Milan, Italy. The INTREPID study is the first sham-controlled double-masked trial to evaluate the effectiveness and safety of a one-time radiation therapy in conjunction with as-needed anti-VEGF injections for the treatment of wet AMD.
Thursday, May 03, 2012/Oraya Therapeutics Achieves Successful INTREPID Study Outcomes With a Non-Invasive Radiation Therapy for Wet AMD
Oraya Therapeutics, Inc. today announced that the INTREPID clinical trial of radiation therapy has met its primary endpoint of reduction in anti-VEGF injections for patients with wet age-related macular degeneration (wet AMD).
Tuesday, May 17, 2011 / Oraya Completes Enrollment in Sham-Controlled Study of Radiation for Wet AMD
Oraya Therapeutics, Inc. today announced that it has completed enrollment of its INTREPID clinical trial in Europe. The study is the first sham-controlled, double-masked trial to evaluate the effectiveness and safety of radiation therapy in conjunction with standard of care anti-VEGF injections for the treatment of wet age-related macular degeneration (AMD).
Wednesday, April 07, 2010 / Oraya Therapeutics Granted European CE Mark for the IRay Stereotactic Radiotherapy System
Oraya Therapeutics, Inc. announces today that a leading European notified body has granted approval to designate the CE mark to Oraya’s IRay stereotactic radiotherapy system. Under development since 2007, the IRay is designed specifically to treat diseases of the eye, and the technology enables precise delivery of low energy X-rays for the treatment of wet age-related macular degeneration.
Tuesday, January 05, 2010 / Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD
Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD.
Tuesday, October 20, 2009 / Oraya Therapeutics to present at Ophthalmology Innovations Summit
The Ophthalmology Innovation Summit (OIS), to be held at the Palace Hotel in San Francisco on October 22, 2009, will bring together leaders in the development of ophthalmic products, drugs, and devices. Oraya therapeutics will present a summary of its innovative technology, currently undergoing clinical evaluation for the treatment of wet macular degeneration. Additional information can be found at http://www.ophthalmologysummit.com.
Tuesday, August 04, 2009 / Oraya Therapeutics Names JIM TAYLOR as President and Chief Executive Officer
Appointment of seasoned executive will support development of company’s age-related macular degeneration treatment
Monday, July 20, 2009 / Oraya Therapeutics Raises $42 MILLION in Series C Financing
Company to begin international multi-center clinical trials for age-related macular degeneration treatment
